Ninepoint Cannabis & Alternative Health Fund - Series F

Ninepoint Cannabis & Alternative Health Fund

Formerly Alternative Health Fund

NPP5421

Ninepoint Cannabis & Alternative Health Fund

Overview

A more health-conscious consumer, an aging population, and legalization of cannabis have introduced new investment opportunities in the alternative health care sector.

Ninepoint Cannabis & Alternative Health Fund can help investors benefit from:

Increasing demand for alternative healthcare

The use of nutraceuticals and cannabis to treat and prevent disease is expected to grow as new applications increase.
Access to an early stage sector

With the legalization of cannabis, the industry is anticipating high growth in medical and recreational use.
Aging demographics

A rise in healthcare expenditures, driven by an aging global population, is pushing consumers to seek cheaper alternatives to treat chronic conditions.
Focus on reducing volatility

Active management helps to reduce the risk of investing in the volatile cannabis sector by investing in liquid securities and allocating to other nutraceutical sectors.

Fund Objective

The Fund’s objective is to achieve growth by investing primarily in equity securities of companies engaged in nutrition, nutraceuticals and new forms of medicines and pharmaceutical solutions.

Investment Team

Ninepoint Partners Sub Advised by Faircourt Asset Management

Ninepoint Partners Sub Advised by Faircourt Asset Management

Faircourt Asset Management Inc. is an employee owned investment management company, widely recognized as an innovator in the Canadian fund industry. Faircourt was founded in 2002 and has established a reputation for innovative investment solutions. Faircourt created UIT Funds in 2016, offering unique investment themes for Canadian investors. The firm manages and advises closed end funds, mutual funds and institutional mandates with approximately $650 million in assets under administration.
View Full Bio
Charles Taerk

President & Chief Executive Officer, Faircourt Asset Management - Sub-Advisor

Charles Taerk

President & Chief Executive Officer, Faircourt Asset Management - Sub-Advisor

Mr. Taerk is a co-founder of Faircourt Asset Management Inc. Mr. Taerk has been President and CEO since inception of Faircourt in 2002. From 1999 to 2001, Vice President and Managing Director for Charles Schwab Canada, Co., and a member of its Executive Committee. His responsibilities included leading the development of Investment Banking, Syndication as well as Institutional Research. Prior to that, Mr. Taerk was in the Corporate Finance group at Porthmeor Securities, where he worked from 19...
View Full Bio
Douglas Waterson, CPA, CA, CFA

Chief Financial Officer & Portfolio Manager, Faircourt Asset Managment - Sub-Advisor

Douglas Waterson, CPA, CA, CFA

Chief Financial Officer & Portfolio Manager, Faircourt Asset Managment - Sub-Advisor

Mr. Waterson brings over 10 years of financial management experience to the Trust. Prior to joining the Manager, Mr. Waterson worked as a Senior Supervisor at the Office of the Superintendent of Financial Institutions (Canada) (OSFI), where he was responsible for monitoring and conducting risk assessments of Schedule I banks. From 2000 to 2001, Mr. Waterson worked as an Analyst in the Investment Banking Group at Charles Schwab Canada, Co. where he was responsible for the initial review of pro...
View Full Bio

Performance

Compound Returns

As at 5/31/2024 (Series F) NPP5421

Compound Returns
MTD %	YTD %	1Y %	3Y %	5Y %	10Y %	Inception %^†
-2.21 As at 6/28/2024	7.99	15.55	-18.13	-8.10	-	5.17

^†Inception Date: August 4, 2017

Growth of $10,000 Invested

As at 5/31/2024 (Series F) NPP5421

Risk Tolerance

Low
Low - Med
Medium
Med - High
High

Portfolio

As at 5/31/2024

Geographic Allocation

Geographic Allocation
Sector	Weight %
Canada	53.48
United States	42.09

Top Ten Holdings

Issuer Name
Abbott Laboratories
Costco Wholesale Corporation
Cresco Labs Inc
Eli Lilly And Company
Green Thumb Industries Inc
Johnson & Johnson
Merck & Co Inc
Terrascend Corp
Trulieve Cannabis Corp
Verano Holdings Corp

Statistical Analysis

As at 5/31/2024 (Series F) NPP5421

Statistics	Fund	Index (TR CAN/US Health Care Blended Index)
Cumulative Return	41.01%	-28.39%
Growth of 10K	$14,101.29	$7,161.42
Sharpe Ratio	0.00	0.00
Standard Deviation	27.00%	28.00%
Total Down Months	41	46
Total Positive Months	40	41

Facts, Fees & Fund Codes

Facts
Facts
Fund Type	North American Equity Growth
Inception Date	Series A: 3/27/2017 Series F: 8/4/2017
Registered Tax Plan Status	Eligible
Distributions	-
Performance Fee	-
Minimum Initial Investment	$500
Minimum Subsequent Investment	$25
Minimum Investment Term	20 days (1.5% penalty)
Redemptions	Daily
Valuations	Daily

Fees
Fees
Management Fee	Series A: 2.25% Series D: 1.25% Series F: 1.25%

Fund Codes
Fund Codes
Series A	NPP5420
Series D	NPP5422
Series F	NPP5421

Documents

All returns and fund details are a) based on Series F shares; b) net of fees; c) annualized if period is greater than one year; d) as at 4/30/2024. Top ten holdings, sector allocation and geographic allocation as at 4/30/2024. Top ten holdings based on % of net asset value. Sector allocation based on % of net asset value. Geographic allocation based on % of net asset value and excludes cash. Numbers may not add up due to rounding. Cash and cash equivalents include non-portfolio assets and/or liabilities.

The rate of return is used only to illustrate the effects of the compound growth rate and is not intended to reflect future values of the investment fund or returns on investment in the investment fund.

The Fund is generally exposed to the following risks: Cannabis sector risk; Concentration risk; Currency risk; Cybersecurity risk; Derivatives risk; Exchange traded funds risk; Foreign investment risk; Inflation risk; Market risk; Regulatory risk; Securities lending, repurchase and reverse repurchase transactions risk; Series risk; Specific issuer risk; Sub-adviser risk; Tax risk.

Ninepoint Partners LP is the investment manager to a number of funds (collectively, the “Funds”). Commissions, trailing commissions, management fees, performance fees (if any), and other expenses all may be associated with investing in the Funds. Please read the prospectus carefully before investing. The indicated rates of return for series F units of the Funds for the period ended 4/30/2024 are based on the historical annual compounded total returns including changes in unit value and reinvestment of all distributions or dividends and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. This communication does not constitute an offer to sell or solicitation to purchase securities of the Funds.

The information contained herein does not constitute an offer or solicitation by anyone in the United States or in any other jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation. Prospective investors who are not resident in Canada should contact their financial advisor to determine whether securities of the Fund may be lawfully sold in their jurisdiction.

Ninepoint Partners LP: Toll Free: 1.866.299.9906. Dealer Services: CIBC Mellon GSSC Record Keeping Services: Toll Free: 1.877.358.0540